Elixxer Ltd. (ELXR)

Overview

Elixxer Ltd. is a distinguished cannabis investment company that operates within various global regions, including Canada, Australia, Italy, Jamaica, and Switzerland. The company focuses on leveraging opportunities in the cultivation, production, and/or sale of medical cannabis as well as cannabis-derived products, primarily targeting the pharmaceutical sector. Originally operating under the name LGC Capital Ltd., it underwent a significant rebranding to become Elixxer Ltd. in August 2019. This strategic move signaled a refreshed focus and direction in the rapidly evolving cannabis industry. Incorporated in 2004 and headquartered in Montreal, Canada, Elixxer Ltd. stands as a key player in the financial landscape of the cannabis market, reflecting years of experience and a commitment to investing in the growth and development of medicinal cannabis operations across various legal jurisdictions.

Products and Services

• Investment in Cultivation

Elixxer Ltd. allocates resources to fund the cultivation of high-quality medical cannabis. This includes investing in agricultural technology and operations that specialize in growing cannabis under regulated environments to ensure the production of pharmaceutical-grade cannabis plants.

• Production

The company invests in the production phase of medical cannabis, which involves the processing, refining, and manufacturing of cannabis-derived products. Their involvement ensures the availability of a comprehensive range of products suitable for therapeutic use, adhering to stringent quality control measures.

• Sale of Medical Cannabis and Cannabis-derived Products

Elixxer Ltd. extends its portfolio to the commercial side by investing in companies that handle the sale and distribution of medical cannabis and its derivatives. This includes partnerships and collaborations with pharmacies, dispensaries, and healthcare providers to make these products accessible to patients in need, aligning with legal compliance and market demand.